On May 8, the board of directors of Japan Takeda and Irish pharmaceutical giant Shire reached an agreement on the bid, and Takeda will acquire Shire for 46 billion pounds (about US$62.1 billion). This is the largest overseas acquisition by a Japanese company in history and the largest merger in the pharmaceutical industry since 2000.
According to PharmExec (Pharmaceutical Manager Magazine) ranking 2017 global pharmaceutical companies TOP50 released based on prescription drug sales, Takeda ranked 19th with US$127.73 billion in revenue, while pharmaceutical giant Shire acquired rare companies Dyax, Baxalta. After waiting, the ranking is raised to 22nd place.
How large will the combined volume of two global TOP10 drug companies be? Endpoints editor John Carroll commented, “If based on revenue, Takeda CEO Christophe Weber can proudly tell the world that Takeda has entered the global Top10 pharmaceutical camp.”
According to the revenue figures of foreign companies’ 2017 financial statements, we can see that after the merger of Takeda and Shire, the operating income can indeed be ranked eighth. As it turned out, Gilead had spent a year cramming into TOP10 with Sovaldi, and Takeda took only a moment to acquire Shire…
Seeing that Takeda has been promoted to the top 10 in the world, you may be more concerned about when China’s pharmaceutical companies can be ranked globally. In fact, according to the ranking of global TOP50 pharmaceutical companies in 2017, the threshold is the sales revenue of 21.34 US dollars for prescription drugs, and Hengrui’s 2017 operating income is 13.8 billion yuan, equivalent to 2.156 billion US dollars, entering the TOP 50 seems to be within reach.